$6.42
42.67% day before yesterday
Nasdaq, Aug 01, 10:20 pm CET
ISIN
US35104E1001
Symbol
FDMT

4D Molecular Therapeutics Inc Stock price

$6.42
+2.27 54.70% 1M
+0.49 8.26% 6M
+0.85 15.26% YTD
-10.77 62.65% 1Y
-2.59 28.75% 3Y
-16.58 72.09% 5Y
-16.58 72.09% 10Y
-16.58 72.09% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+1.92 42.67%
ISIN
US35104E1001
Symbol
FDMT
Industry

Key metrics

Basic
Market capitalization
$297.4m
Enterprise Value
$-24.0m
Net debt
positive
Cash
$321.4m
Shares outstanding
46.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
14,870.2 | 68.8
EV/Sales
negative | negative
EV/FCF
0.2
P/B
0.6
Financial Health
Equity Ratio
91.1%
Return on Equity
-31.5%
ROCE
-41.6%
ROIC
-109.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.0k | $4.3m
EBITDA
$-196.0m | $-228.1m
EBIT
$-203.3m | $-226.8m
Net Income
$-176.4m | $-168.1m
Free Cash Flow
$-157.0m
Growth (TTM | estimate)
Revenue
-100.0% | 10,710.0%
EBITDA
-1.7% | -26.0%
EBIT
-3.2% | -20.7%
Net Income
-1.9% | -4.5%
Free Cash Flow
-97.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-852,347.8% | -5,276.1%
EBIT
-884,026.1%
Net
-767,126.1% | -3,886.6%
Free Cash Flow
-682,443.5%
More
EPS
$-3.2
FCF per Share
$-3.4
Short interest
8.1%
Employees
201
Rev per Employee
$0.0
Show more

Is 4D Molecular Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

4D Molecular Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a 4D Molecular Therapeutics Inc forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from 4D Molecular Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.02 0.02
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
24% 24%
246,100%
- Research and Development Expense 154 154
11% 11%
770,650%
-196 -196
2% 2%
-980,200%
- Depreciation and Amortization 7.29 7.29
68% 68%
36,450%
EBIT (Operating Income) EBIT -203 -203
3% 3%
-1,016,630%
Net Profit -176 -176
2% 2%
-882,200%

In millions USD.

Don't miss a Thing! We will send you all news about 4D Molecular Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

4D Molecular Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
EMERYVILLE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive results from the SPECTRA clinical trial evaluating 4D-150 in pat...
Neutral
GlobeNewsWire
10 days ago
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the America...
Neutral
GlobeNewsWire
22 days ago
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company's board o...
More 4D Molecular Therapeutics Inc News

Company Profile

4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for optalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Head office United States
CEO David Kirn
Employees 201
Founded 2013
Website 4dmoleculartherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today